NCT03093714View on ClinicalTrials.gov

A Study to Evaluate Safety, PK and PD of FDL169 in Cystic Fibrosis Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

August 23, 2017

Primary Completion Date

April 3, 2018

Study Completion Date

April 3, 2018

Conditions
Cystic Fibrosis
Interventions
DRUG

FDL169

CFTR corrector

DRUG

Placebo

Placebo for FDL169

Trial Locations (14)

3004

The Alfred Hospital, Melbourne

4032

The Prince Charles Hospital, Chermside

4101

Mater Misericordiae Ltd, South Brisbane

93093

Klinik Donaustauf, Zentrum für Pneumologie, Donaustauf

Unknown

FN v Motole, Pediatrická klinika, Centrum cystické fibrózy, Brno

FN v Motole, Pediatrická klinika, Centrum cystické fibrózy, Prague

Charité - Universitätsmedizin Berlin CVK, Berlin

Ruhrlandklinik, Essen

Universitätsklinikum Frankfurt, Frankfurt

BT9 7AB

NICRN Respiratory Research Office, Belfast City Hospital, Belfast

L14 3PE

Research Dept., Liverpool Heart and Chest Hospital, Liverpool

SW3 6NP

Royal Brompton Hospital, London

M23 9QZ

The Medicines Evaluation Unit (MEU), Manchester

SO16 6YD

NIHR Wellcome Trust Clinical Research Facility, Southampton

All Listed Sponsors
lead

Flatley Discovery Lab LLC

OTHER

NCT03093714 - A Study to Evaluate Safety, PK and PD of FDL169 in Cystic Fibrosis Subjects | Biotech Hunter | Biotech Hunter